REVIEWS  MELANOMA UPDATES 2009 

Giornale Italiano di Dermatologia e Venereologia 2009 February;144(1):1-26

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Metastatic malignant melanoma

Markovic S. N. ¹, Erickson L. A. ¹, Flotte T. J. ¹, Kottschade L. A. ¹, Mcwilliams R. R. ¹, Jakub J. W. ¹, Farley D. R. ¹, Tran N. V. ¹, Schild S. E. ², Olivier K. R. ¹, Vuk-Pavlovic S. ¹, Sekulic A. ², Weenig R. H. ¹, Pulido J. S. ¹, Quevedo J. F. ¹, Vile R. G. ¹, Wiseman G. A. ¹, Stoian I. ¹, Pittelkow M. R. ¹

¹ Mayo Clinic, Rochester, MN, USA 2 Mayo Clinic, Scottsdale, AZ, USA

Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multi-disciplinary clinical management.